Last reviewed · How we verify
PV-001-DC
At a glance
| Generic name | PV-001-DC |
|---|---|
| Sponsor | PrimeVax Immuno-Oncology Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma (PHASE1)
- Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma (PHASE1)
- Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PV-001-DC CI brief — competitive landscape report
- PV-001-DC updates RSS · CI watch RSS
- PrimeVax Immuno-Oncology Inc. portfolio CI